BERLIN, Germany, January 10, 2023 / B3C newswire / -- ProBioGen announced today a new non-exclusive collaboration with Boehringer Ingelheim on ProBioGen's DirectedLuck® transposase technology.
Berlin, Germany & Zurich, Switzerland – April 12, 2023-- ProBioGen and ImmunOs Therapeutics announce the extension of their partnership for further large-scale manufacturing of clinical material for ...
ATLANTA, GA and BERLIN, Germany, Sept. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against ...
Under an agreement, ProBioGen will develop a stable cell-line for and manufacture an anti-cancer antibody for Chiome using its proprietary cancer cell-killing technology. ProBioGen, a service and ...
Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and ProBioGen, a leading CDMO in biologics, vaccines and viral vectors, announce that ...
ProBioGen, a leading CDMO of innovative solutions and services for biopharmaceutical development, announced the execution of services and license agreements with Mapp Biopharmaceutical, Inc. to ...
ProBioGen will collobarate with NextPoint Therapeutics to develop and manufacture its lead antibody candidate. ProBioGen announced on Aug. 17, 2022 that it has closed a Master Service Agreement with ...
ProBioGen announced that it has signed an agreement with Emergent BioSolutions for a non-exclusive commercial multi-product license and option agreement under which Emergent will be granted broad ...
Berlin, March 31, 2010 - ProBioGen AG, a leading biotechnology company in cell engineering and production of biopharmaceuticals, today announced that Dr. Volker Sandig has been appointed to Chief ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results